Form 4: Recursion Pharmaceuticals Director Stock Sale

Director Christopher Gibson reported the net settlement of 22,821 shares of Class A Common Stock for tax obligations.

Summary

• Director Christopher Gibson disposed of 22,821 shares of Class A Common Stock on May 15, 2026.
• The transaction was a net settlement to satisfy tax withholding obligations related to restricted stock units.
• The shares were sold at a price of $3.04 per share.
• Following this transaction, the director retains direct ownership of 883,735 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax withholding rather than a strategic divestment.

Positives

• The transaction was a routine tax-related net settlement rather than a discretionary open-market sale.
• The director maintains a significant equity stake in the company.

Negatives

• The transaction resulted in a reduction of the director's direct shareholding.

Risks

• None identified; this is a standard administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that net settlement transactions for tax obligations are standard practice for corporate insiders in the biotechnology sector and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and tax compliance practices observed across the pharmaceutical and biotech industries.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a mandatory tax settlement.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Form 4, Insider Trading, Director, Stock Settlement